HighTower Advisors LLC Has $8.08 Million Stock Holdings in DexCom, Inc. $DXCM

HighTower Advisors LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 127.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 121,697 shares of the medical device company’s stock after buying an additional 68,251 shares during the period. HighTower Advisors LLC’s holdings in DexCom were worth $8,077,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in DXCM. Brighton Jones LLC grew its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC grew its stake in shares of DexCom by 6.3% in the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after buying an additional 196 shares during the period. Empowered Funds LLC grew its stake in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after buying an additional 436 shares during the period. Focus Partners Wealth grew its stake in shares of DexCom by 13.2% in the 1st quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after buying an additional 841 shares during the period. Finally, NewEdge Advisors LLC boosted its stake in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $72.01 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The stock’s 50 day moving average price is $63.87 and its 200-day moving average price is $66.18. The company has a market capitalization of $27.79 billion, a PE ratio of 30.77, a PEG ratio of 1.19 and a beta of 1.40. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $0.32 EPS. The company’s revenue was up 15.0% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Truist Financial reissued a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Weiss Ratings raised DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. Raymond James Financial set a $81.00 price objective on DexCom in a research note on Friday, May 1st. Canaccord Genuity Group set a $82.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Finally, Sanford C. Bernstein set a $77.00 price objective on DexCom in a research note on Friday, May 1st. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $82.21.

Insider Transactions at DexCom

In other news, insider Kevin R. Sayer sold 26,759 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. The trade was a 6.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,871 shares of company stock worth $2,306,638 in the last 90 days. Insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.